Tag: Enjaymo
Press release: European Commission approves Enjaymo® (sutimlimab) for the treatment of hemolytic anemia in adults with cold agglutinin disease – 11/17/2022 at 6:50 p.m.
[ad_1] The European Commission approves Enjaymo ® (sutimlimab) for treatment of hemolytic anemia in adults suffering from cold agglutinin disease Enjaymo is the first and only approved treatment option for…
Sanofi: European favorable opinion for Enjaymo
[ad_1] Receive the value of the day selected by The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable,…
Sanofi: European favorable opinion for Enjaymo – 09/16/2022 at 16:21
[ad_1] (CercleFinance.com) – The Scientific Committee of the European Medicines Agency (EMA) yesterday issued a favorable opinion concerning the granting of a marketing authorization for Enjaymo, Sanofi’s treatment for patients…
Sanofi: European positive opinion for Enjaymo
[ad_1] (CercleFinance.com) – The Scientific Committee of the European Medicines Agency (EMA) yesterday issued a favorable opinion concerning the granting of a marketing authorization for Enjaymo, Sanofi’s treatment for patients…
Sanofi: approval of Enjaymo in the United States
[ad_1] (CercleFinance.com) – Sanofi announces that the United States FDA has approved Enjaymo (sutimlimab-jome) to reduce the need for red blood cell transfusions to treat hemolysis in adults with cold…
Sanofi: approval of Enjaymo in the United States – 02/07/2022 at 08:00
[ad_1] (CercleFinance.com) – Sanofi announces that the United States FDA has approved Enjaymo (sutimlimab-jome) to reduce the need for red blood cell transfusions to treat hemolysis in adults with cold…
Sanofi: FDA approves Enjaymo to treat cold agglutinin disease
[ad_1] PARIS (Agefi-Dow Jones)–The pharmaceutical group Sanofi announced Friday evening that the Food and drug administration (FDA), the American health authority, had approved its drug Enjaymo, to reduce the use…